Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin?

American Heart Journal

Volumn 147, Issue 2, 2004, Pages 293-300

  Cotter, Gad ^a   Shemesh, Eyal ^d,e   Zehavi, Miriam ^b   Dinur, Irit ^a   Rudnick, Abraham ^c   Milo, Olga ^a   Vered, Zvi ^a   Krakover, Rikardo ^a   Kaluski, Edo ^a   Kornberg, Abraham ^b  

^a Cardiology Institute   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HEART INFARCTION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTE; UNSTABLE ANGINA PECTORIS;

EID: 10744228434     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.011     Document Type: Article

References (19)

1. Gaziano JM, Manson JE, Ridker PM. Primary and secondary prevention of coronary heart disease. In: Braunwald E, editor. Heart Disease. Philadelphia, Pa: WB Saunders; 2001. p. 1052-3.
2. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
3. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
5. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. Arch Intern Med 1997;157:1921-9.
6. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolal in patients with acute myocardial infarction, I: mortality results. JAMA 1982;247:1707-14.
7. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1994;270:742-4.
8. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-41.
9. Rich MW, Beckham V, Wittenberg C. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
10. Shemesh E, Rudnick A, Kaluski E, et al. A prospective study of posttraumatic stress symptoms and nonadherence in survivors of a myocardial infarction (MI). Gen Hosp Psychiatry 2001;23:215-22.
11. Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41.
12. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 1999;84:404-9.
13. Weber AA, Liesener S, Hohlfeld T, et al. Forty mg of aspirin are not sufficient to inhibit platelet function under conditions of limited compliance. Thromb Res 2000;97:365-7.
14. Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial: an evaluation of self-report and microelectronic monitoring. Arch Fam Med 1996;5:297-300.
15. Johnson SB. Measuring adherence. Diabetes Care 1992;15:1658-67.
16. Dew MA, Roth LH, Thompson ME, et al. Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transplant 1996;15:631-45.
17. Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral vascular disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Result From the OPUS-TIMI 16 Study. Am Heart J 2003;145:622-7.
18. Dargie HJ. Effect of corvedilol on outcome after myocardiol infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
19. Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet 2002;359:2129-30.